Helus Pharma™ Announces US$50 Million Underwritten Offering
Helus Pharma priced a $50 million underwritten public offering of 10,309,280 common shares at $4.85 per share. Net proceeds are intended to fund the Phase 3 APPROACH trial of HLP003 for major depressive disorder, with data expected in Q4 2026, as well as HLP004, HLP005, and general corporate purposes.
Key figures
- Drug Name
- HLP003
- Deal Value Usd
- 50000000
- Phase Of Trial
- Phase 3
- Offering Price
- 4.85
- Shares Offered
- 10309280
- Clinical data expected
- Q4 2026
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.